Centaurus Financial - we invest in your success
CuraDebit Free Debt Analysis
  Home > Fortune 500 Companies > Quest Diagnostics.

Quest Diagnostics.


Quest Diagnostics is a fortune 500 stock listed company trading under DGX and is listed on the NYSE. The company has good stock performance results.
 
Quest Diagnostics Incorporated is the nation's leading provider of diagnostic testing, information and services, announced that for the fourth quarter ended December 31, 2005, net income increased to 130 million dollars, or 0.64 dollar per diluted share, compared to 126 million dollars, or 0.60 dollar per share in 2004. Included in the results were pretax charges of 16 million dollars, or 0.06 dollar per share, related to a product hold at the company's test kit manufacturing subsidiary.

Fourth quarter revenues grew 11.8 percent over the prior year level to 1.4 billion dollars. The acquisition of LabOne, which was completed on November 1, 2005, increased consolidated revenues by approximately 7 percent. The performance at NID reduced consolidated revenue growth by approximately 1 percent. Clinical testing revenues grew 8.7 percent, with LabOne contributing approximately 3 percent. Clinical testing volume, measured by the number of requisitions, increased 5.8 percent and revenue per requisition increased 2.8 percent.

Fourth quarter operating income was 234 million dollars, or 16.3 percent of revenues, compared to 221 million dollars, or 17.2 percent of revenues, in 2004. Operating income as a percentage of revenues compared to the prior year was reduced by approximately 2 percent due to the performance at NID, and approximately 0.5 percent due to the inclusion of LabOne.

For the full year 2005, net income increased to 546 million dollars, and earnings per diluted share increased 13 percent to 2.66 dollars. Revenues for the full year increased 7.4 percent to 5.5 billion dollars. Operating income was 968 million dollars, or 17.6 percent of revenues, compared to 891 million dollars, or 17.4 percent of revenues in 2004. Operating income as a percentage of revenues compared to the prior year was reduced by approximately 1 percent due to the performance at NID. Cash from operations increased to 852 million dollars, compared to 799 million dollars in 2004. During 2005, the company repurchased 7.8 million common shares for 390 million dollars, paid dividends totaling 70 million dollars, and made capital expenditures of 224 million dollars.

The Company offers the widest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care.

Back to Fortune 500 Companies

 
 
Infinit-i